Merck Manual

Please confirm that you are a health care professional

honeypot link

Hypophosphatemic Rickets

(Vitamin D–Resistant Rickets)

By

Christopher J. LaRosa

, MD, Perelman School of Medicine at The University of Pennsylvania

Last full review/revision Dec 2020| Content last modified Dec 2020
Click here for Patient Education
Topic Resources

Hypophosphatemic rickets is a disorder characterized by hypophosphatemia, defective intestinal absorption of calcium, and rickets or osteomalacia unresponsive to vitamin D. It is usually hereditary. Symptoms are bone pain, fractures, and growth abnormalities. Diagnosis is by serum phosphate, alkaline phosphatase, and 1,25-dihydroxyvitamin D3 levels. Treatment is oral phosphate plus calcitriol; burosumab is given for X-linked hypophosphatemia.

Sporadic acquired cases sometimes are caused by benign mesenchymal tumors that produce a humoral factor that decreases proximal renal tubular resorption of phosphate (tumor-induced osteomalacia).

General reference

  • 1. Bitzan M, Goodyer PR: Hypophosphatemic rickets. Pediatr Clin N Am 66(1):179–207, 2019. doi: 10.1016/j.pcl.2018.09.004

Pathophysiology of Hypophosphatemic Rickets

The observed abnormality is decreased proximal renal tubular resorption of phosphate, resulting in renal phosphate wasting and hypophosphatemia Hypophosphatemia Hypophosphatemia is a serum phosphate concentration 2.5 mg/dL (0.81 mmol/L). Causes include alcohol use disorder, burns, starvation, and diuretic use. Clinical features include muscle weakness... read more . This defect is due to circulating factors called phosphatonins. The principle phosphatonin in hereditary hypophosphatemic rickets is fibroblast growth factor-23 (FGF-23). Decreased intestinal calcium and phosphate absorption also occurs. Deficient bone mineralization is due to low phosphate levels and osteoblast dysfunction rather than to the low calcium and elevated parathyroid hormone (PTH) levels as in calcipenic rickets (see Vitamin D Deficiency and Dependency Vitamin D Deficiency and Dependency Inadequate exposure to sunlight predisposes to vitamin D deficiency. Deficiency impairs bone mineralization, causing rickets in children and osteomalacia in adults and possibly contributing... read more ). Because 1,25-dihydroxyvitamin D3 levels are normal to slightly low, a defect in conversion is presumed; hypophosphatemia would normally cause elevated 1,25-dihydroxyvitamin D3 levels.

There are several forms of hypophosphatemic rickets (see table Forms of Hereditary Hypophosphatemic Rickets Forms of Hereditary Hypophosphatemic Rickets* Hypophosphatemic rickets is a disorder characterized by hypophosphatemia, defective intestinal absorption of calcium, and rickets or osteomalacia unresponsive to vitamin D. It is usually hereditary... read more ). A form of hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is known to occur due to mutations in the proximal tubule type 2c sodium-phosphate cotransporter (NaPi2c). Defective phosphate transport and hypophosphatemia in this case result in appropriately increased 1,25-dihydroxyvitamin D3 levels, thus leading to hypercalciuria.

Table
icon

Symptoms and Signs of Hypophosphatemic Rickets

The disease manifests as a spectrum of abnormalities, from hypophosphatemia alone to growth retardation and short stature to severe rickets or osteomalacia. Children usually present after they begin walking, with bowing of the legs and other bone deformities, pseudofractures (ie, x-ray findings in osteomalacia that may represent areas of prior stress fractures that have been replaced by inadequately mineralized osteoid vs areas of bony erosions), bone pain, and short stature. Bony outgrowth at muscle attachments may limit motion.

Rickets of the spine or pelvis, dental enamel defects, and tetany that occur in dietary vitamin D deficiency are rarely present in hypophosphatemic rickets.

Patients with HHRH may present with nephrolithiasis and/or nephrocalcinosis.

Diagnosis of Hypophosphatemic Rickets

  • Serum levels of calcium, phosphate, alkaline phosphatase, 1,25-dihydroxyvitamin D3, PTH, FGF-23, and creatinine

  • Urinary phosphate and creatinine levels (for calculation of the tubular reabsorption of phosphate)

  • Bone x-rays

Serum phosphate levels are depressed, but urinary phosphate excretion is large. Serum calcium and PTH are normal, and alkaline phosphatase often is elevated. Hypophosphatemia-induced stimulation of calcitriol production does not occur. Typically, calcidiol levels are normal, whereas calcitriol levels are normal to low. In calcipenic rickets, hypocalcemia is present, hypophosphatemia is mild or absent, and urinary phosphate is not elevated.

Treatment of Hypophosphatemic Rickets

  • Oral phosphate and calcitriol

  • Burosumab for X-linked hypophosphatemia

Treatment of hypophosphatemic rickets consists of neutral phosphate solution or tablets. Starting dose in children is 10 mg/kg (based on elemental phosphorus) 4 times a day. Phosphate supplementation lowers ionized calcium concentrations and further inhibits calcitriol conversion, leading to secondary hyperparathyroidism and exacerbating urinary phosphate wasting. Therefore, oral vitamin D is given as calcitriol, initially 5 to 10 ng/kg 2 times a day. This, however, is not the case with HHRH or HHN (hypophosphatemia, hypercalcemia, and nephrocalcinosis), where 1,25-dihydroxyvitamin D3 levels are elevated and dosing with calcitriol can be detrimental.

Phosphate dose may need to be increased to achieve bone growth or relieve bone pain. Diarrhea may limit oral phosphate dosage. Increase in plasma phosphate and decrease in alkaline phosphatase concentrations, healing of rickets, and improvement of growth rate occur. Hypercalcemia, hypercalciuria, and nephrocalcinosis with reduced renal function may complicate treatment. Patients undergoing treatment need frequent follow-up evaluations.

Burosumab is an anti–FGF-23 monoclonal antibody that has become the treatment of choice for X-linked hypophosphatemia (XLH) and has replaced the conventional therapy described above (1 Treatment reference Hypophosphatemic rickets is a disorder characterized by hypophosphatemia, defective intestinal absorption of calcium, and rickets or osteomalacia unresponsive to vitamin D. It is usually hereditary... read more ). Dosing in children < 10 kg is started at 1 mg/kg (rounded to nearest 1 mg) subcutaneously every 2 weeks. For children 6 months to < 18 years and > 10 kg, starting dose is 0.8 mg/kg (rounded to the nearest 10 mg) subcutaneously every 2 weeks. For adults ≥ 18 years, starting dose is 1 mg/kg (rounded to the nearest 10 mg) subcutaneously every 4 weeks. The dose may be titrated upwards according to the manufacturer’s instructions to a maximum of 2 mg/kg or 90 mg as needed to normalize serum phosphate.

Adults with oncogenic rickets may dramatically improve once the mesenchymal tumor that causes the disorder is removed. Otherwise, oncogenic rickets is treated with calcitriol 5 to 10 ng/kg orally 2 times a day and elemental phosphorus 250 mg to 1 g orally 3 or 4 times a day.

Treatment reference

Key Points

  • Decreased renal resorption of phosphate results in renal phosphate wasting and hypophosphatemia.

  • There is deficient bone mineralization due to low phosphate levels and osteoblast dysfunction.

  • Children have growth retardation, bone pain and deformities (eg, leg bowing), and short stature.

  • Patients with hypophosphatemic rickets with hypercalciuria (HHRH) may present with nephrolithiasis and/or nephrocalcinosis.

  • Diagnose by finding low serum phosphate levels, elevated urinary phosphate, and normal serum calcium and parathyroid hormone.

  • Treat with oral phosphate supplements and, except for HHRH, vitamin D (given as calcitriol).

  • Use burosumab for X-linked hypophosphatemia.

More Information

The following is an English-language resource that may be useful. Please note that THE MANUAL is not responsible for the content of this resource.

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version

OTHER TOPICS IN THIS CHAPTER

Professionals also read

Test your knowledge

Mumps
Mumps is an acute, contagious, systemic viral disease caused by a paramyxovirus. It is spread by droplets or saliva and probably enters through the nose and mouth. After a 12- to 24-day incubation period, headache, anorexia, malaise, and low-grade fever usually develop. Then several other symptoms develop over the next few days. Of these symptoms, edema of which of the following structures is most likely to peak on the 2nd day and typically last 5 to 7 days? 
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID

Also of Interest

Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
TOP